Market revenue in 2020 | USD 16.4 million |
Market revenue in 2028 | USD 26.7 million |
Growth rate | 6.3% (CAGR from 2020 to 2028) |
Largest segment | Immunological disorders |
Fastest growing segment | Cardiovascular Disorders |
Historical data | 2016 - 2019 |
Base year | 2020 |
Forecast period | 2021 - 2028 |
Quantitative units | Revenue in USD million |
Market segmentation | Neurological Disorders, Immunological Disorders, Hematology Diseases, Endocrine & Metabolism Diseases, Cancer, Musculoskeletal Disorders, Cardiovascular Disorders, Dermatology Disease |
Key market players worldwide | Quest Diagnostics Inc, Centogene NV Ordinary Shares, Invitae Corp, Eurofins Scientific SE, PerkinElmer, Macrogenics Inc, Fulgent Genetics Inc, Myriad Genetics Inc, Labcorp Holdings Inc, OPKO Health Inc, 3billion, ARUP Laboratories, Strand Life Sciences, Ambry Genetics, REALM IDx, Inc., Baylor Genetics, Health Network Laboratories, PreventionGenetics, Biora Therapeutics, CooperSurgical, Artemis DNA |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to rare disease genetic testing market will help companies and investors design strategic landscapes.
Immunological disorders was the largest segment with a revenue share of 13.41% in 2020. Horizon Databook has segmented the Spain rare disease genetic testing market based on neurological disorders, immunological disorders, hematology diseases, endocrine & metabolism diseases, cancer, musculoskeletal disorders, cardiovascular disorders, dermatology disease covering the revenue growth of each sub-segment from 2016 to 2028.
Professionals at SJD Barcelona hospital have enabled doctors to diagnose rare or ultra-rare diseases through Face2Gene, a smartphone application that accelerates diagnosing rare or ultra-rare conditions. Such ongoing activities in the country are anticipated to boost revenue growth in the coming years.
Launch of the Spanish Undiagnosed Rare Diseases Program in response to the challenges pertaining to address the needs of patients with rare diseases post success of the Undiagnosed Diseases Program (UDP) in the U.S. is anticipated to accelerate revenue generation in this market. Spain UDP delivers a multidisciplinary approach to patients seeking diagnosis and treatment solutions.
Horizon Databook provides a detailed overview of country-level data and insights on the Spain rare disease genetic testing market , including forecasts for subscribers. This country databook contains high-level insights into Spain rare disease genetic testing market from 2016 to 2028, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account